FOLH1 and cancer: This is in line with previously published results reporting on substantial PSMA expression on tumor vessels in various cancer entities (Chang et al, 1999); (iii) the most important difference with regard to binding of 10B3 and J591 could be documented in SCC of the lung: here we observed pronounced and significantly higher binding of 10B3 to tumor cells when compared to J591, whereas binding to the neovasculature was rather similar with both antibodies (Fig 1C and D, and EV2B).